Quest’s New Collaboration to Evaluate WGS for Developmental Delays
The collaboration seeks to demonstrate the value of WGS as a first-line genetic test for postnatal diagnosis of developmental delay disorders.
Read MorePosted by Andy Lundin | Apr 4, 2024 | Sequencing Systems |
The collaboration seeks to demonstrate the value of WGS as a first-line genetic test for postnatal diagnosis of developmental delay disorders.
Read MorePosted by Andy Lundin | Mar 29, 2024 | Company News |
Labcorp has long been a partner to Prelude and its network, providing clinical laboratory and FDA-approved donor testing within each clinic.
Read MorePosted by Andy Lundin | Mar 28, 2024 | Molecular Diagnostics |
A single genetic test could potentially replace the current two-step approach to diagnosing rare developmental disorders in children.
Read MorePosted by Andy Lundin | Mar 25, 2024 | Molecular Diagnostics |
Nucleus Genomics launched a DNA analysis product aimed at expanding access to the benefits of personalized medicine.
Read MorePosted by Andy Lundin | Mar 22, 2024 | Unknown Origin & Other Cancer Types |
The U.S. Patent and Trademark Office issued a patent to Myriad Genetics aimed at strengthening its ability to deliver a MRD assay to market.
Read More